<SEC-DOCUMENT>0001213900-20-016870.txt : 20200707
<SEC-HEADER>0001213900-20-016870.hdr.sgml : 20200707
<ACCEPTANCE-DATETIME>20200707162311
ACCESSION NUMBER:		0001213900-20-016870
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200707
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200707
DATE AS OF CHANGE:		20200707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		201016312

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea123906-8k_optimizerxcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 7, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OptimizeRx Corporation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 33%">Nevada</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 32%">001-38543</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 33%">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction <BR>
of incorporation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer <BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center">400 Water Street, Suite 200, Rochester, MI</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Registrant&rsquo;s telephone number, including
area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under
the Securities Act (17CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Trading symbol</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name of each exchange on<BR>
 which registered</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">OPRX</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Nasdaq Capital Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 7, 2020, we issued a press release
announcing that we have secured two new SaaS-based enterprise-level engagements that provide the full spectrum of access to our
nationwide digital healthcare platform. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SECTION 9 &ndash; Financial Statements
and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 93%; text-align: justify"><A HREF="ea123906ex99-1_optimizerx.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Press release, dated July 7, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Douglas Baker</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Douglas Baker</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date July 7, 2020</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea123906ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED JULY 7, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OptimizeRx Sales Momentum Continues with
Two New Enterprise-level Engagements Added to its Digital Health Platform</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ROCHESTER, Mich. &ndash; July 7, 2020 &ndash; </B>OptimizeRx
Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, has secured two new
SaaS-based enterprise-level engagements that provide the full spectrum of access to the company&rsquo;s nationwide digital healthcare
platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One win represents a new platform client and the other the transition
of a legacy client to the company&rsquo;s new enterprise solution suite. The two deals have on average an annual contract value
of $3.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;These wins demonstrate the exceptional capabilities and
reach of our solutions and their proven ability to deliver value to our clients,&rdquo; said OptimizeRx chief commercial officer,
Steve Silvestro. &ldquo;Our enterprise engagements have been producing strong results due to the improved interoperability between
our point-of-care and direct-to-patient solutions, with this all working together to deliver better outcomes for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;As pharma continues to see restricted travel and limited
patient access to healthcare providers due to COVID-19, our platform has become a &lsquo;must-have&rsquo; solution for maintaining
the flow of critical communications between industry and healthcare providers regardless of location.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx&rsquo;s newly integrated digital health platform
enables unprecedented transparency into patient medication behavior, and provides access to patient-provider-pharma communications
across the care continuum and in a variety of care settings. By improving these communications, pharmaceutical companies, healthcare
providers and payers can more efficiently and effectively address patient medication affordability and therapeutic adherence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx CEO,&nbsp;William Febbo, commented: &ldquo;We are
encouraged by the continued conversion of our pipeline of enterprise-level opportunities and the resulting buildup in recurring
revenue. As these more expansive enterprise deployments better address the need for greater digital connectivity, they also provide
us more revenue per customer and a more consistent revenue stream.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our up-sell opportunity for converting just our legacy
clients from individual solutions to enterprise platform engagements remains greater than $100 million,&rdquo; added Febbo. &ldquo;While
naturally this will not be realized overnight, these two wins, making it six in total so far in 2020, demonstrate the strength
of our new sales team and solid results from our integrated platform approach.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About OptimizeRx</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">OptimizeRx Corporation (NASDAQ: OPRX)
is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused
on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence
and care management. OptimizeRx&rsquo;s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support
on specialty medications and patient financial assistance directly within a provider&rsquo;s workflow through leading electronic
health platforms. OptimizeRx&rsquo;s fully integrated platform supports the real-time exchange of information, improving provider
knowledge and patient engagement, and ultimately leading to healthier outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">For more information, follow the company on&nbsp;<U>Twitter</U>,&nbsp;<U>LinkedIn</U>&nbsp;or
visit&nbsp;<U>www.optimizerx.com</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>Important Cautions Regarding Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible'
and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by,
or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include,
but are not limited to, the effect of government regulation, competition, and other material risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OptimizeRx Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Doug Baker, CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel (248) 651-6568 x807</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dbaker@optimizerx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maira Alejandra, Media Relations Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel (754) 245-7070</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">malejandra@optimizerx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ron Both, CMA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel (949) 432-7557</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">oprx@cma.team</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !5 9@# 2(  A$! Q$!_\0
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MM:O_ ,+OU>+?:V^HWMS!;/Y2B+=!'&WE@1YV */[=*_AU_X-=/\ D^?]NO\
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M\-/_ -(B?PZ_\$DP/^(B[]M,D D:]^VW@D#(S\9M#S@]L]#CMQ7]Q5?PZ_\
M!)/_ )6+OVU/^P]^VU_ZN;1*_N*IY_\ [WA_^Q?@?_3$2L5\</\ KS3_ ",;
MQ'_R+VO?]@;5/_2&>OXGO^#3O_DO?[</_9/?A;_ZG/Q K^V'Q&0/#VO$\?\
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M?R\=T?\ #B3_ ()*YS_PQ9\/\^O_  E/Q1S_ .IY7ZVT5O\ 7\?_ -!V,_\
M"FM_\L*]K5_Y^3_\#E_F?D]IO_!#/_@E#I&IZ9K.F_L9^ ;74]&U/3M9TR[3
MQ/\ $YGM-3TF]@U'3KM%D\<O&TEK>VT%PBR(\;-&!(CH64_K#116-6O7KN+K
MUZU9Q3475JSJ<J=K\O/*5KM)M*U[(F4I2^*4I6VYFW;[VSS[XG_"?X9?&KP7
MK/PX^+W@'PC\3/ 7B"'R-9\(>-] TSQ+X?OU 81R3:;JMM<VXN;<N7M+N-$N
MK.;;/:S0S*KC\6_'W_!MO_P2N\;ZQ<:OIWPO^)'PW6YF:=]'^'?Q?\9:;H,;
M,=S)::7KUUXDBL(,_=M[%K>&(?+"D:!5'[RT5=#%XK#7^KXBM14G=JG4E&+?
M=QUBW;2_+>W4<9SA\$Y1]&U^&WX'Y#_ +_@A3_P3#_9XUS3_ !5X=_9PTOQ]
MXJTFYAO-+U[XT>(/$'Q6:PN[<AX;JUT'Q7?W?A&&YCD"RQ7*>'1/#(B/!+$1
M7ZZ0PQ6\4<$$4<,,,:0PPQ(L<4442A(XHHT 2..- %1$5550%4  "I**BM7K
MXB2GB*]:O)*R=6I*?*GNH\S:2\DDA2E*3O*3D^[;?YA7BWQJ_9Z^$G[0NE:)
MHOQ<\*_\)5IOAW4Y=8T>V_M;6=)^QZA/:/8RW'FZ+J&GRS![61XS'.\L8SO5
M X##VFBN'&8/"9AAJV"Q^%P^-PF(BH5\+BJ5.OAZT%*,U&K1JQE"<5.$))2B
MTI0B]XHRG3A5A*G4A&<)*TH3BI1DKIV<6FFKI/7JD?&/A#_@GY^R9X#\5^'/
M&WA7X7#3/$WA/6++7] U+_A+/&=U]AU;3I?.L[K[->>()[6X\F4!_)N8)8'Z
M/&PR*^SJ**YLLR;*,EIU:.499@,KI5ZBJUJ> PE#"0JU(P]G&I4C0ITXSG&F
MN2,I)M1]U66A-*A1H1<:%&G1C)W<:4(TXMVM=J*2;MI>U[!7Q]X__8+_ &5/
MB?XRU_Q]XT^%EOJ7BKQ/=I?Z[J5OXB\5:2FH7RV\-JUY)8Z3K=E8QW,T4$1N
M98;:-KF;?<3[YY'D;[!HIYED^59S1IX?-LMP.9T*515J=''X6ABZ5.JHR@JL
M(5Z=2,:G)*4.>-GRMQ=T[!5H4:Z4:U*G5BGS*-2$9I2M:Z4D[.S:NK:.Q\L_
M"?\ 8P_9S^!OC"/QY\+O <_A?Q1'IE]HYOX?%/BV^BGTS41";JRN[#4]<O+"
MZADDM[>9!/;2&&>WAGA:.6-6#/VL?V*_V:OVWO NA_#K]I?X8:3\1O#?AGQ5
MI'C'P]]JGO=+UC1-8TN\MY[A-,U[2;BTU>STSQ!90/H?BK2H+Q+'Q#H5U<:?
MJ$,H%N]O]4T5IE>78#)*4:&38/#951C4G6C1RZC3P=*-:HDJE6-.A&$%4FHI
M3DHIRLN;FL51I4\.E&A3A1BFY*-**IKF>C=HI*[LKNVO6YD:!H&A^%=#T?PU
MX9T?3/#WAWP]I=CHFA:#HMC;:9H^C:/I=M%9:;I>E:;9QPV=AI]C:0PVUG9V
ML,4%M!''%%&B(%&O117:];MN[>K;U;;W;;O=WUN^I9XA\3_V<_@W\9?$?@3Q
M;\2? ND>)M?^'.J?VGX;O[U'## >1--U:.)ECUS1([YHM5CT;5%N=/34[6"Z
M6 %KA9_;0,8 &%'  Z 8P !Q@# XQQT'%.HKEHX'!X>OBL3A\+AZ&)QTZ53&
MXBE1I4ZV+J4:2HTIXFK"$9UY4Z25.#JRFXP]U/2Y$:<(RG.,(1E4:=248Q4I
MN,5&+FTDY-15DVW9:!111746%%%% !1110 4444 %%%% !7YZ6W_  2Z_8[M
M/VT)?V_8/!'B=?VF)M;N/$#^*S\0O&3:"=3NO S?#J:4>#&U<^&!$WA9C:"
M:;Y2W'^G*HNOWM%%:4ZM6ES^RJ3I^TA*G4Y).//3E\4)6M>+ZIZ,:E*-[-JZ
ML[.UT^C\C]"Z***S$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
